A
bispecific monoclonal antibody (
BsMAb,
BsAb) is an artificial
protein that is composed of fragments of two different
monoclonal antibodies and consequently binds to two different types of
antigen. The most widely used application of this approach is in
cancer immunotherapy, where BsMAbs are engineered that simultaneously bind to a
cytotoxic cell (using a receptor like
CD3) and a target like a
tumour cell to be destroyed.